Shilpa Medicare Q1 FY27 Results: Revenue Grows 43%, PAT Surges 115%, Credit Rating Upgraded to AA-

What Happened ?

Shilpa Medicare started FY27 with record quarterly financial performance driven by consistent growth across its three core businesses—API, Formulations and Biologics. Management highlighted that investments made in R&D, manufacturing capabilities, regulatory approvals and integrated CDMO infrastructure are beginning to translate into stronger commercial outcomes.

During the quarter, the company also received a credit rating upgrade from A+ to AA-, reflecting improving financial strength, stronger return ratios and disciplined capital management. 

key details

Record Financial Performance:

• Revenue reached a record ₹469 crore, growing 43% YoY.
• EBITDA increased to ₹139 crore.
• EBITDA margin remained strong at 30%.
• PAT more than doubled to ₹101 crore.
• Operating PBT increased 84% YoY.
• Finance costs declined 36% YoY.

Note:

• Management attributed the performance to broad-based growth across all business verticals and improving operating leverage. 

API Business Continues to Expand:

• API revenue remained the largest contributor at 47% of total revenue.
• Core API business recorded approximately 15% YoY growth.
• Specialty CDMO continued gaining traction through new customer additions in developed markets.
• More than 20 API products remain under development.
• Expansion of the oncology API manufacturing block is progressing and is expected to be completed by the end of FY27.
• Capacity expansion is underway for key products including UDCA and Tranexamic Acid.

Note:

• Specialty CDMO, peptides and polymer businesses continue strengthening Shilpa’s higher-value API portfolio. 

Formulations Business Delivers Triple-Digit Growth:

• Formulations contributed 42% of total revenue.
• Revenue increased by over 100% YoY.
• US formulations revenue reached ₹45 crore.
• Europe formulations revenue increased to ₹57 crore, growing 84% YoY.
• Domestic formulations revenue grew 179% YoY to ₹24 crore.
• Strong traction continued following the launch of NorUDCA (Noduca™).

Note:

• Growth was supported by commercialization of complex products, new approvals and expanding international market penetration. 

Biologics & Biosimilars Pipeline Advances:

• Biologics contributed 11% of total revenue.
• Partnership signed with Orion Corporation to co-develop a Nivolumab biosimilar for Europe.
• Human trials for Nivolumab are underway.
• Aflibercept biosimilar targets India launch during FY27.
• Four new biosimilar development programs were added during the quarter.
• ADC (Antibody Drug Conjugate) platform continued progressing toward human studies.

Note:

• Management continues focusing on high-value biosimilars targeting large global therapeutic markets. 

CDMO Business Strengthens:

• One CDMO program received US FDA approval.
• Two new late-stage Japanese customer opportunities were secured.
• Commercial supplies to a European customer are expected to begin during 2HFY27.
• Strong peptide order book provides healthy revenue visibility.
• Integrated ADC manufacturing facility commissioned at Dharwad.

Note:

• The integrated CDMO platform positions Shilpa as one of the few Indian companies offering end-to-end services across APIs, biologics and ADC manufacturing. 

Product Pipeline & Strategic Developments:

• NorUDCA continues expanding through three marketing partnerships and Shilpa’s own brand.
• Rotigotine Transdermal Patch received EMA approval ahead of the planned FY27 European launch.
• Ondansetron Long-Acting Injection is targeting an India launch during FY27.
• Development continues across Abraxane, Xtandi, Semaglutide, Recombinant Human Albumin and multiple oncology products.
• More than 20 new formulation approvals were received during Q1 FY27.

Note:

• The diversified pipeline across complex generics, specialty products and biologics supports long-term growth visibility. 

Balance Sheet & Capital Efficiency:

• Credit rating upgraded from A+ to AA-.
• Adjusted ROCE improved to 18.3%.
• Net Debt-to-EBITDA reduced to 1.3x.
• Gross Block increased to ₹2,328 crore.
• Ongoing investments continue supporting future manufacturing capacity.

Note:

• Management expects further operating leverage as recently commissioned facilities achieve higher utilization levels. 

Risk Analysis

Summary:

• While Shilpa Medicare delivered record quarterly performance, future execution depends on successful commercialization of its development pipeline, regulatory approvals, expansion projects and continued growth across CDMO and biologics businesses.

Key Risks:

• Delays in regulatory approvals across major markets.
• Clinical trial risks for novel biologics and biosimilars.
• Commercialization delays for pipeline products.
• Dependence on successful CDMO execution.
• Foreign regulatory and compliance risks.
• Higher capital investment requirements for expansion projects.

Worst Case:

• Delays in regulatory approvals, slower commercialization of novel products or weaker CDMO execution could moderate revenue growth despite a strong development pipeline.

Risk Level: Medium

Conclusion

• Highest-ever quarterly Revenue, EBITDA and PAT achieved.
• Strong growth recorded across API, Formulations and Biologics.
• Credit rating upgraded from A+ to AA-.
• Integrated R&D and manufacturing platform continues strengthening competitive positioning.
• Global partnerships expanded across novel therapies and biosimilars.
• Management remains confident of delivering stronger growth during FY27 through pipeline commercialization and operating leverage.